ANIKA THERAPEUTICS INC (ANIK)
US0352551081 - Common Stock
We assign a fundamental rating of 4 out of 10 to ANIK. ANIK was compared to 588 industry peers in the Biotechnology industry. ANIK has a great financial health rating, but its profitability evaluates not so good. ANIK is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ANIK had negative earnings in the past year.
In the past year ANIK has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ANIK reported negative net income in multiple years.
ANIK had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -30.55%, ANIK is doing good in the industry, outperforming 72.60% of the companies in the same industry.
ANIK has a better Return On Equity (-38.95%) than 76.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.55% | ||
| ROE | -38.95% | ||
| ROIC | N/A |
ROA(3y)-11.21%
ROA(5y)-6.39%
ROE(3y)-14.24%
ROE(5y)-8.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ANIK (61.85%) is better than 81.34% of its industry peers.
In the last couple of years the Gross Margin of ANIK has declined.
ANIK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.37%
GM growth 5Y-2.54%
2. Health
2.1 Basic Checks
ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ANIK has been increased compared to 1 year ago.
Compared to 5 years ago, ANIK has more shares outstanding
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ANIK has an Altman-Z score of 5.48. This indicates that ANIK is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.48, ANIK belongs to the best of the industry, outperforming 81.68% of the companies in the same industry.
ANIK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.48 |
ROIC/WACCN/A
WACC9.34%
2.3 Liquidity
A Current Ratio of 5.26 indicates that ANIK has no problem at all paying its short term obligations.
ANIK has a Current ratio (5.26) which is in line with its industry peers.
A Quick Ratio of 3.76 indicates that ANIK has no problem at all paying its short term obligations.
The Quick ratio of ANIK (3.76) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.76 |
3. Growth
3.1 Past
The earnings per share for ANIK have decreased strongly by -507.87% in the last year.
ANIK shows a small growth in Revenue. In the last year, the Revenue has grown by 6.68%.
Measured over the past years, ANIK shows a quite strong growth in Revenue. The Revenue has been growing by 9.56% on average per year.
EPS 1Y (TTM)-507.87%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1164.71%
Revenue 1Y (TTM)6.68%
Revenue growth 3Y8.49%
Revenue growth 5Y9.56%
Revenue growth Q2Q8.46%
3.2 Future
ANIK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.61% yearly.
Based on estimates for the next years, ANIK will show a quite strong growth in Revenue. The Revenue will grow by 10.24% on average per year.
EPS Next Y100.09%
EPS Next 2Y41.09%
EPS Next 3Y27.46%
EPS Next 5Y16.61%
Revenue Next Year3.22%
Revenue Next 2Y4.2%
Revenue Next 3Y5.5%
Revenue Next 5Y10.24%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ANIK. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 5013.73, the valuation of ANIK can be described as expensive.
Based on the Price/Forward Earnings ratio, ANIK is valued cheaply inside the industry as 93.32% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 21.49. ANIK is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5013.73 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ANIK's earnings are expected to grow with 27.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.09%
EPS Next 3Y27.46%
5. Dividend
5.1 Amount
ANIK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ANIKA THERAPEUTICS INC
NASDAQ:ANIK (4/26/2024, 7:00:00 PM)
After market: 25.57 0 (0%)25.57
-0.01 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap374.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5013.73 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.55% | ||
| ROE | -38.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 61.85% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-507.87%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y100.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.68%
Revenue growth 3Y8.49%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y